 "Alembic Pharma dips 5% on disappointing September quarter results")
Shares of Alembic Pharmaceuticals dipped 5 per cent to Rs 757 on the BSE in the intra-day trade on Thursday after the company's consolidated profit declined 49 per cent year on year (YoY) at Rs 169 crore in September quarter (Q2FY22), due to lower revenue. The pharmaceutical company had posted profit of Rs 333 crore in the year-ago quarter.
At 10:45 am, the stock was trading 3.4 per cent lower at Rs 766.20, as compared to a 0.87 per cent decline in the S&P BSE Sensex. It had hit a 52-week low of Rs 720.80 on August 23, 2020.
In Q2FY22, the company's total revenue was down 11 per cent to Rs 1,292 crore from Rs 1,457 crore in Q2FY21. The US revenue declined 40 per cent to Rs 348 crore on YoY basis. However, India business grew 23 per cent to Rs 509 crore over the previous year quarter. Consolidated earnings before interest, tax, depreciation and amortization (ebitda), post R&D, contracted 21 per cent from 31 per cent.
The management believes the current US sales figures ($47 million per quarter) are the new base, and these are expected to improve hereafter, led by new launches.
"Alembic Pharma's subdued performance in US/API was offset by a better-than-expected show in the Domestic Formulation (DF) segment. The YoY declining trend in the US business has reached a trough with the limited impact of price erosion and an increased pace of launches going forward," Motilal Oswal Financial Services said.
The brokerage firm has lowered its FY22E/FY23E EPS estimate by 7.5 per cent/5.8 per cent, factoring in a delay in successful compliance at injectables sites, gradual revival in US sales, and higher RM/logistics costs.
Meanwhile, in exchange filing Alembic Pharma said that the United States Food and Drug Administration (USFDA) recently inspected the company’s injectable facility (F-3) site and issued Form 483 with 10 observations. "None of the observations are related to data integrity and management believes that they are addressable. The Company is preparing the response to the observations, which will be submitted to the USFDA," the company said.
At 10:45 am, the stock was trading 3.4 per cent lower at Rs 766.20, as compared to a 0.87 per cent decline in the S&P BSE Sensex. It had hit a 52-week low of Rs 720.80 on August 23, 2020.
In Q2FY22, the company's total revenue was down 11 per cent to Rs 1,292 crore from Rs 1,457 crore in Q2FY21. The US revenue declined 40 per cent to Rs 348 crore on YoY basis. However, India business grew 23 per cent to Rs 509 crore over the previous year quarter. Consolidated earnings before interest, tax, depreciation and amortization (ebitda), post R&D, contracted 21 per cent from 31 per cent.
The management believes the current US sales figures ($47 million per quarter) are the new base, and these are expected to improve hereafter, led by new launches.
"Alembic Pharma's subdued performance in US/API was offset by a better-than-expected show in the Domestic Formulation (DF) segment. The YoY declining trend in the US business has reached a trough with the limited impact of price erosion and an increased pace of launches going forward," Motilal Oswal Financial Services said.
The brokerage firm has lowered its FY22E/FY23E EPS estimate by 7.5 per cent/5.8 per cent, factoring in a delay in successful compliance at injectables sites, gradual revival in US sales, and higher RM/logistics costs.
Meanwhile, in exchange filing Alembic Pharma said that the United States Food and Drug Administration (USFDA) recently inspected the company’s injectable facility (F-3) site and issued Form 483 with 10 observations. "None of the observations are related to data integrity and management believes that they are addressable. The Company is preparing the response to the observations, which will be submitted to the USFDA," the company said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%